Chemotherapy drug delivery from calcium phosphate nanoparticles

International Journal of Nanomedicine

Volumn 2, Issue 4, 2007, Pages 667-674

  Cheng, Xingguo ^a   Kuhn, Liisa ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Calcium phosphate; Chemotherapy; Cisplatin; Drug delivery; Nanoparticle

Indexed keywords

ANTINEOPLASTIC AGENT; CALCIUM PHOSPHATE; CHLORIDE; CISPLATIN; NANOPARTICLE; POLY(METHYL METHACRYLATE);

ARTICLE; BINDING KINETICS; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG STABILITY; ELECTRICITY; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OVARY CANCER; PRECIPITATION; SUSTAINED RELEASE FORMULATION; SYNTHESIS; TIME;

ANTINEOPLASTIC AGENTS; CALCIUM PHOSPHATES; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DIFFUSION; DRUG CARRIERS; FEMALE; HUMANS; MATERIALS TESTING; NANOPARTICLES; OVARIAN NEOPLASMS; PARTICLE SIZE;

EID: 48449092610     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Allen TM, Moase EH. 1996. Therapeutic opportunities for targeted liposomal drug delivery. Advanced Drug Delivery Reviews, 21:117-33.
2. Ambruosi A, Khalansky AS, Yamamoto H, et al. 2006. Biodistribution of ate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. Journal Of Drug Targeting, 14:97-105.
3. Aoki H. 1994. Medical applications of hydroxyapatite. Tokyo: Takayama Press System Center Co., Inc. p 106-9.
4. Bathe C, Bartlett J, Kong LG, et al. 2004. Silica particles: a novel drug-delivery system. Advanced Materials, 16:1959-66.
5. Barroug A, Glimcher MJ. 2002. Hydroxyapatite crystals as a local delivery system for cisplatin: adsorption and release of cisplatin in vitro. Journal of Orthopaedic Research, 20:274-80.
6. Barroug A, Kuhn LT, Gerstenfeld LC, et al. 2004. Interactions of cisplatin with calcium phosphate nanoparticles: in vitro controlled adsorption and release. Journal of Orthopaedic Research, 22:703-8.
7. Benghuzzi H. 2000. Long-term sustained delivery of 3′-azido-2′,3′-dideoxythymidine in vivo by means of HA and TCP delivery devices. Biomedical Sciences Instrumentation, 36:343-8.
8. Bisht S, Bhakta G, Mitra S, et al. 2005. pDNA loaded calcium phosphate nanoparticles: highly efficient non-viral vector for gene delivery. International Journal of Pharmaceutics, 288:157-68.
9. Bonhomme L, Mathieu MC, Amdidouche D, et al. 1992. Intratumor treatment of C3H mouse mammary carcinoma with 5-fluorouracil adsorbed on activated charcoal particles. Anti-Cancer Drugs, 3:261-6.
10. Dong Y, Feng S-S. 2006. Nanoparticles of poly(D,L-lactide)/methoxy poly(ethylene glycol)-poly(D,L-lactide) blends for controlled release of paclitaxel. Journal Of Biomedical Materials Research. Part A, 78:12-19.
11. Elliott J. 1994. Structure and chemistry of the apatites and other calcium orthophosphates. Elsevier. 389 p.
12. Farokhzad OC, Karp JM, Langer R. 2006. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opinion On Drug Delivery, 3:311-24.
13. Foger F, Noonpakdee W, Loretz B, et al. 2006. Inhibition of malarial topoisomerase II in Plasmodium falciparum by antisense nanoparticles. International Journal of Pharmaceutics, 319:139-46.
14. Fung LK, Saltzman WM. 1997. Polymeric implants for cancer chemotherapy. Advanced Drug Delivery Reviews, 26:209-30.
15. Gorbunoff MJ. 1984a. The interaction of proteins with hydroxyapatite: I. Role of protein charge and structure. Analytical Biochemistry, 136:425-32.
16. Gorbunoff MJ. 1984b. The interaction of proteins with hydroxyapatite: II. Role of acidic and basic groups. Analytical Biochemistry, 136:433-9.
17. Gregoriadis G. 1995. Engineering liposomes for drug delivery: progress and problems. Trends in Biotechnology, 13:527-37.
18. He Q, Mitchell AR, Johnson SL, et al. 2000. Calcium phosphate nanoparticle adjuvant. Clinical and Diagnostic Laboratory Immunology, 7:899-903.
19. Hong RL, Huang CJ, Tseng YL, et al. 1999. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: Is surface coating with polyethylene glycol beneficial? Clinical Cancer Research, 5:3645-52.
20. Itokazu M, Sugiyama T, Ohno T, et al. 1998. Development of porous apatite ceramic for local delivery of chemotherapeutic agents. Journal of Biomedical Materials Research, 39:536-8.
21. Lee ES, Na K, Bae YH. 2005. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. Journal of Controlled Release, 103:405-18.
22. Legeros RZ, Mijares D, LeGeros JP, et al. 2005. Amorphous calcium phosphate (ACP): formation and stability. Key Engineering Materials, 284-6:7-10.
23. Lin R, Shi Ng L, Wang C-H. 2005. In vitro study of anticancer drug doxorubicin in PLGA-based microparticles. Biomaterials, 26:4476-85.
24. Liu TY, Chen SY, Liu DM, et al. 2005. On the study of BSA-loaded calcium-deficient hydroxyapatite nano-carriers for controlled drug delivery. Journal of Controlled Release, 107:112-21.
25. Liu Z, Ballinger JR, Rauth AM, et al. 2003. Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres. The Journal of Pharmacy and Pharmacology, 55:1063-73.
26. Long D, Repta A. 1981. Cisplatin: chemistry, distribution and biotransformation. Bipharm Drug Disposition, 2:1-16.
27. Mandel N, Riese R. 1991. Crystal-cell interactions: crystal binding to rat renal papillary tip collecting duct cells in culture. American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, 17:402-6.
28. Marcucci F, Lefoulon F. 2004. Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. Drug Discovery Today, 9:219-28.
29. Minko T, Dharap SS, Pakunlu RI, et al. 2004. Molecular targeting of drug delivery systems to cancer. Current Drug Targets, 5:389-406.
30. Minko T, Kopeckova P, Pozharov V, et al. 1998. HPMA copolymer bound adriamycin overcomes MDRI gene encoded resistance in a human ovarian carcinoma cell line. Journal of Controlled Release: Official Journal of the Controlled Release Society, 54:223-33.
31. Mizushima Y, Ikoma T, Tanaka J, et al. 2006. Injectable porous hydroxyapatite microparticles as a new carrier for protein and lipophilic drugs. Journal of Controlled Release: Official Journal of the Controlled Release Society, 110:260-5.
32. Rogers-Foy JM, Powers DL, Brosnan DA, et al. 1999. Hydroxyapatite composites designed for antibiotic drug delivery and bone reconstruction: a caprine model. Journal of Investigative Surgery, 12:263-75.
33. Spenlehauer G, Vert M, Benoit JP, et al. 1989. In vitro and In vivo degradation of poly(D,L lactide/glycolide) type microspheres made by solvent evaporation method. Biomaterials, 10:557-63.
34. Vauthier C, Dubernet C, Chauvierre C, et al. 2003. Drug delivery to resistant rumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. Journal of Controlled Release, 93:151-60.
35. Vicent MJ, Duncan R. 2006. Polymer conjugates: nanosized medicines for treating cancer. Trends in Biotechnology, 24:39-47.
36. Welzel T, Radtke I, Meyer-Zaika W, et al. 2004. Transfection of cells with custom-made calcium phosphate nanoparticles coated with DNA. Journal of Materials Chemistry, 14:2213-17.
37. Yamamura K, Iwata H, Osada T, et al. 1994. Anticancer effects of adriamycin-loaded hydroxyapatite implants determined in a swarm rat chondrosarcoma model. Japanese Journal of Pharmacology, 65:289-91.
38. Yi YW, Kim JH, Kang HW, et al. 2005. A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution. Pharmaceutical Research, 22:200-8.
39. Zhang JX, Xu Q, Tanaka H, et al. 2006. Improvement of the dispersion of Al203 slurries using EDTA-4Na. Journal of the American Ceramic Society, 89:1440-2.
40. Zhang K, Colwell JC. 2004. Bioceramics, New Orleans: Trans Tech Publications.